Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

J.P. Brown, C. Roux, P.R. Ho, M.A. Bolognese, J. Hall, H.G. Bone, S. Bonnick, J.P. van den Bergh, I. Ferreira, P. Dakin, R.B. Wagman, C. Recknor

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (a parts per thousand yen1 risk factor) were transitioned to denosumab or a monthly oral BP. Denosumab-treated subjects had significantly greater increases in bone mineral density and decreases in bone turnover in this 12-month study. A clinical need exists to manage patients who are suboptimally adherent to oral BPs and remain at higher risk for fracture. Here, we compare the effects on bone mineral density (BMD) and bone turnover of transitioning such patients to denosumab or monthly oral BP (ibandronate or risedronate). In two previous multicenter, open-label studies, postmenopausal women a parts per thousand yen55 years previously treated with, though suboptimally adherent to, a daily or weekly BP were randomized to denosumab 60 mg subcutaneously every 6 months (N = 852) or oral BP 150 mg monthly (N = 851) for 12 months. In this combined post-hoc analysis, a subset of higher risk subjects was identified, and the percentage changes from baseline in BMD and serum C-telopeptide of type I collagen (sCTX-1) were assessed. In the overall population, denosumab was associated with greater gains in BMD at 12 months than monthly oral BP at the total hip, femoral neck, and lumbar spine (p < 0.0001 for all). In higher risk subjects, denosumab led to greater gains in BMD than oral BPs at the total hip (2.2 vs 0.8 %), femoral neck (1.8 vs 0.3 %), and lumbar spine (3.7 vs 1.4 %) (p < 0.0001 for all). Denosumab also led to greater decreases in sCTX-1 in the overall population and higher risk subjects at months 1 and 6 (p < 0.0001 for both). Adverse events and serious adverse events were generally similar between treatment groups. Transitioning to denosumab was well tolerated and more effective in increasing BMD and reducing bone turnover than cycling to a monthly oral BP treatment in subjects who remained at higher fracture risk despite suboptimal BP treatment.
Original languageEnglish
Pages (from-to)1953-1961
Number of pages9
JournalOsteoporosis International
Volume25
Issue number7
DOIs
Publication statusPublished - Jul 2014

Keywords

  • Adherence
  • Bone mineral density
  • Bone turnover
  • Denosumab
  • Postmenopausal osteoporosis
  • Oral bisphosphonate
  • OVARIECTOMIZED CYNOMOLGUS MONKEYS
  • RANDOMIZED-OPEN-LABEL
  • HUMAN RANKL ANTIBODY
  • NONVERTEBRAL FRACTURES
  • MEDICATION ADHERENCE
  • ALENDRONATE THERAPY
  • OSTEOPOROSIS
  • STRENGTH
  • MARKERS
  • IMPACT

Cite this